ASCO 2021 Breast Cancer In-depth

Talazoparib Is Active in gBRCA1/2 Mutation-Positive, HER2-Negative Early Breast Cancer

Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.

Durvalumab Improves Survival When Added to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Durvalumab improved invasive disease-free survival, distant disease-free survival, and overall survival.

Genomic Signature May Identify Breast Cancer Patients Who Can Safely Forgo Adjuvant Radiotherapy

The signature was prognostic for locoregional recurrence.

Chemotherapy Doesn’t Increase the Risk of COVID-19 or Related Death in Patients with Breast Cancer, Study Suggests

Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.

Endocrine Therapy Proves Noninferior to Chemotherapy in HR+, HER2+ Metastatic Breast Cancer

Endocrine therapy was associated with fewer adverse events.

Age and Stage at Breast Cancer Diagnosis Don’t Account for Racial Disparities in Distant Metastases

Black patients were more likely than White patients to have distant metastases.